

FluMist® Influenza Vaccine Live, Intranasal Spray, 2009-2010 Formula

Catalog No. NR-17600

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

MedImmune, LLC

Product Description:

NR-17600 is a live, trivalent vaccine that produces the hemagglutinin and neuraminidase surface antigens from an influenza A/Brisbane/59/07 (H1N1)-like virus (A/South Dakota/6/07), an A/Brisbane/10/07 (H3N2)-like virus (A/Uruguay/716/07) and the B/Brisbane/60/08 virus that were predicted to circulate in the United States during the 2009 to 2010 influenza season.¹ The three viruses in NR-17600 are cold-adapted (*ca*), temperature-sensitive (*ts*) and attenuated (*att*). Each virus contains the two RNA segments encoding the hemagglutinin and neuraminidase from the antigenically relevant wild-type circulating strain. Each virus contains the six internal gene segments from a master donor virus responsible for the replication properties and the *ca*, *ts* and *att* phenotypes.

NR-17600 was prepared from virus propagated in the allantoic cavity of embryonated chicken eggs. The allantoic fluid was harvested, pooled and clarified by filtration. The virus was concentrated by ultracentrifugation and diluted with stabilizing buffer to obtain the final sucrose and potassium phosphate concentrations. Ethylene diamine tetracetic acid (EDTA) was added to the dilution buffer for the H3N2 strain. The viral harvests were sterile-filtered to produce monovalent bulks. The monovalent bulks were blended and diluted with stabilizing buffers to attain the desired potency and to produce the trivalent bulk vaccine. The bulk vaccine was then filled directly into individual sprayers for nasal administration.

Please note that this vaccine preparation is being released for research use only and not for human use.

Material Provided:

Each 0.2 mL single-use sprayer contains 10^{6.5-7.5} fluorescent focus units of each of the three live, attenuated strains. Each sprayer also contains 0.188 mg monosodium glutamate, 2.00 mg hydrolyzed porcine gelatin, 2.42 mg arginine, 13.68 mg sucrose, 2.26 mg dibasic potassium phosphate, 0.96 mg monobasic potassium phosphate and < 0.003 µg gentamicin sulfate. NR-17600 contains no preservatives.

Packaging/Storage:

NR-17600 contains a pre-filled, single-use, 0.2 mL sprayer. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: FluMist® Influenza Vaccine Live, Intranasal Spray, 2009-2010 Formula, NR-17600."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Fiore, A. E., et al. "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009." MMWR Recomm. Rep. 58 (2009): 1-52. PubMed: 19644442. Erratum in MMWR Recomm. Rep. 58 (2009): 896-897.

ATCC® is a trademark of the American Type Culture Collection.

